Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

British Journal of Cancer

Volumn 86, Issue 9, 2002, Pages 1449-1456

  Hirsch, F R ^a,b   Varella Garcia, M ^a,b   Franklin, W A ^a,b   Veve, R ^a   Chen, L ^a   Helfrich, B ^a   Zeng, C ^a   Baron, A ^b   Bunn, P A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

FISH; Gene amplification; HER 2 neu; Immunohistochemistry; Lung cancer; Oncogene overexpression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CELL SURFACE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 0037029712     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600286     Document Type: Article

References (32)

1. Testing for erbB-2 by immunohistochemistry in breast cancer
2. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
3. Epidermal growth factor receptor and HER-2-neu mRNA expression in non-small cell lung cancer is correlated with survival
4. Expression of HER-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and relationship to in vitro cytotoxicity by trastuzumab and cytotherapeutic
5. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
6. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
7. Herceptest: Her2 expression and gene amplification in non-small cell lung cancer
8. Cancer statistics, 2001. CA
9. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: A comparative immunohistochemical and fluorescence in situ hybridization study
10. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung
11. Comparison of fluorescence in situ hybridication and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
12. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry
13. P185 expression in human lung adenocarcinomas predicts shortened survival
14. Effects of HER-2/neu expression on survival in non-small-cell lung cancer
15. The Her-2(c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
16. The concordance between the clinical trials assays (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
17. Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein expression
18. Evidence by in situ hybridization that c-erbB-2 proto-oncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas
19. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
20. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
21. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
22. Differential expression of the c-erB-2 gene in human small cell and non-small cell lung cancer
23. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
24. Amplification of c-erbB-2 and aggressive human breast tumors?
25. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
26. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
27. P185 a product of the neu proto-oncogene is a receptorlike protein associated with tyrosine kinase activity
28. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma
29. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations
30. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positive do not get the message
31. R monotherapy in metastatic breast cancer